Regaining compliance with Nasdaq is a significant positive regulatory development for Cyclacel Pharmaceuticals. It removes the risk of delisting, which can improve investor sentiment and potentially increase stock liquidity and attractiveness to institutional investors. The news directly impacts the company and is likely to be viewed positively by the market in the short term.